Organoids Predict Therapeutic Response in Patients With Multi-line Drug-resistant Lung Cancer

This study uses tiny lab-grown tumor models called organoids — made from a patient's own cancer cells — to predict which treatments are most likely to work for patients with lung cancer that has stopped responding to multiple prior therapies. The goal is to match each patient to a personalized treatment plan. **You may be eligible if...** - You are 18 or older - You have non-small cell lung cancer confirmed by biopsy - Your cancer has progressed despite multiple rounds of standard treatment - Your expected survival is at least 3 months - A biopsy of your tumor is accessible **You may NOT be eligible if...** - Your tumor cannot be safely biopsied - You are not well enough to tolerate treatment - You are not willing to follow the study protocol - Your cancer is a different type than what the study accepts Talk to your doctor to see if this trial is right for you.